Mine sisu juurde

EGFR T790M

Lehekülje sisu ei toetata teistes keeltes.
Loo artikkel

See on automaatne vaade, mis põhineb projekti Vikiandmed andmetel.
Artiklit veel pole, kuid saad aidata seda luua.

genetic variant

Välised allikad

dbSNP Reference SNP number
rs121434569[1]
Microsoft Academic ID
2777930144
CIViC variant ID
34[2]
OpenAlex ID
C2777930144[3]
HGVS nomenclature
ENST00000275493.2:c.2369C>T[2]
NM_005228.4:c.2369C>T[2]
NP_005219.2:p.Thr790Met[2]
NC_000007.13:g.55249071C>T[2]
Google Knowledge Graph ID
/g/11bwqm1h47

üksikjuht nähtusest

missense mutation[2]

chromosome

human chromosome 7[2]

genomic assembly: Genome assembly GRCh37

genomic start

55249071[2]

genomic assembly: Genome assembly GRCh37

genomic end

55249071[2]

genomic assembly: Genome assembly GRCh37

biological variant of

EGFR[2]

positive therapeutic predictor for

rociletinib[4]

määramismeetod: CIViC evidence level B

medical condition treated: non-small-cell lung carcinoma

rating: CIViC 4-star trust rating

staurosporine[5]

määramismeetod: CIViC evidence level E

medical condition treated: non-small-cell lung carcinoma

rating: CIViC 1-star trust rating

osimertinib[6]

määramismeetod: CIViC evidence level D

medical condition treated: non-small-cell lung carcinoma

rating: CIViC 3-star trust rating

osimertinib[7]

määramismeetod: CIViC evidence level B

medical condition treated: non-small-cell lung carcinoma

rating: CIViC 4-star trust rating

osimertinib[8]

määramismeetod: CIViC evidence level B

medical condition treated: non-small-cell lung carcinoma

rating: CIViC 3-star trust rating

rociletinib[9]

määramismeetod: CIViC evidence level D

medical condition treated: non-small-cell lung carcinoma

rating: CIViC 3-star trust rating

osimertinib[10][11]

määramismeetod: CIViC evidence level A

medical condition treated: non-small-cell lung carcinoma

rating: CIViC 5-star trust rating

osimertinib[12]

määramismeetod: CIViC evidence level C

medical condition treated: adenocarcinoma of the lung

rating: CIViC 1-star trust rating

osimertinib[13]

määramismeetod: CIViC evidence level C

medical condition treated: adenocarcinoma of the lung

rating: CIViC 2-star trust rating

neratinib[14]

määramismeetod: CIViC evidence level D

medical condition treated: non-small-cell lung carcinoma

rating: CIViC 2-star trust rating

afatinib[15][16]

määramismeetod: CIViC evidence level D

medical condition treated: non-small-cell lung carcinoma

rating: CIViC 2-star trust rating

canertinib[17]

määramismeetod: CIViC evidence level D

medical condition treated: non-small-cell lung carcinoma

rating: CIViC 2-star trust rating

pemetrexed / erlotinib combination therapy[18]

rating: CIViC 3-star trust rating

medical condition treated: non-small-cell lung carcinoma

määramismeetod: CIViC evidence level C

osimertinib[19]

rating: CIViC 2-star trust rating

medical condition treated: non-small-cell lung carcinoma

määramismeetod: CIViC evidence level D

rociletinib[19]

rating: CIViC 2-star trust rating

medical condition treated: non-small-cell lung carcinoma

määramismeetod: CIViC evidence level D

dacomitinib[20]

rating: CIViC 3-star trust rating

medical condition treated: non-small-cell lung carcinoma

määramismeetod: CIViC evidence level D

osimertinib[21]

määramismeetod: CIViC evidence level C

rating: CIViC 2-star trust rating

medical condition treated: pancreatic adenocarcinoma

statement disputed by: EGFR Exon 19 Deletion in Pancreatic Adenocarcinoma Responds to Erlotinib, Followed by T790M-Mediated Resistance.

negative therapeutic predictor for

erlotinib[22]

rating: CIViC 5-star trust rating

medical condition treated: non-small-cell lung carcinoma

määramismeetod: CIViC evidence level A

gefitinib[23][24]

rating: CIViC 3-star trust rating

medical condition treated: non-small-cell lung carcinoma

määramismeetod: CIViC evidence level B

dacomitinib[25]

rating: CIViC 4-star trust rating

medical condition treated: non-small-cell lung carcinoma

määramismeetod: CIViC evidence level B

gefitinib[26]

rating: CIViC 3-star trust rating

medical condition treated: adenocarcinoma of the lung

määramismeetod: CIViC evidence level B

erlotinib[26]

rating: CIViC 3-star trust rating

medical condition treated: adenocarcinoma of the lung

määramismeetod: CIViC evidence level B

erlotinib[24]

rating: CIViC 3-star trust rating

medical condition treated: non-small-cell lung carcinoma

määramismeetod: CIViC evidence level B

afatinib[27]

rating: CIViC 4-star trust rating

medical condition treated: non-small-cell lung carcinoma

määramismeetod: CIViC evidence level B

lapatinib[28]

rating: CIViC 4-star trust rating

medical condition treated: non-small-cell lung carcinoma

määramismeetod: CIViC evidence level D

gefitinib[29]

rating: CIViC 4-star trust rating

medical condition treated: non-small-cell lung carcinoma

määramismeetod: CIViC evidence level C

erlotinib[29]

rating: CIViC 4-star trust rating

medical condition treated: non-small-cell lung carcinoma

määramismeetod: CIViC evidence level C

negative prognostic predictor for

non-small-cell lung carcinoma[30][31]

määramismeetod: CIViC evidence level B

rating: CIViC 4-star trust rating

Viited

  1. ↑ CIViC database
  2. ↑ 2,00 2,01 2,02 2,03 2,04 2,05 2,06 2,07 2,08 2,09 CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/variants/34
  3. ↑ OpenAlex, 26. jaanuar 2022, https://docs.openalex.org/download-snapshot/snapshot-data-format
  4. ↑ CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/646, Rociletinib in EGFR-mutated non-small-cell lung cancer
  5. ↑ CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/278, A systematic profile of clinical inhibitors responsive to EGFR somatic amino acid mutations in lung cancer: implication for the molecular mechanism of drug resistance and sensitivity
  6. ↑ CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/963, AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer
  7. ↑ CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/965, AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer
  8. ↑ CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/966, Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib
  9. ↑ CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/762, Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.
  10. ↑ CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/1592, Osimertinib: First Global Approval
  11. ↑ CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/1867, Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
  12. ↑ CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/1397, Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain
  13. ↑ CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/2157, EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients.
  14. ↑ CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/2162, Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.
  15. ↑ CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/2163, BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
  16. ↑ CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/2164, Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models
  17. ↑ CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/2165, BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
  18. ↑ CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/277, Response to pemetrexed rechallenge after acquired resistance of EGFR-TKI in a patient with advanced NSCLC.
  19. ↑ 19,0 19,1 CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/967, In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer
  20. ↑ CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/2161, PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib
  21. ↑ CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/6006, EGFR Exon 19 Deletion in Pancreatic Adenocarcinoma Responds to Erlotinib, Followed by T790M-Mediated Resistance.
  22. ↑ CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/238, EGFR T790M resistance mutation in non small-cell lung carcinoma
  23. ↑ CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/239, EGFR mutation and resistance of non-small-cell lung cancer to gefitinib
  24. ↑ 24,0 24,1 CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/1667, Heterogeneity of resistance mutations detectable by next-generation sequencing in TKI-treated lung adenocarcinoma
  25. ↑ CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/240, Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors
  26. ↑ 26,0 26,1 CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/1391, Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers
  27. ↑ CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/1863, Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors.
  28. ↑ CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/2160, BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
  29. ↑ 29,0 29,1 CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/2158, Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain
  30. ↑ CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/369, The predictive role of pretreatment epidermal growth factor receptor T790M mutation on the progression-free survival of tyrosine-kinase inhibitor-treated non-small cell lung cancer patients: a meta-analysis
  31. ↑ CIViC database, 23. mai 2022, https://civic.genome.wustl.edu/links/evidence/370, Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients
Pärit leheküljelt "https://et.wikipedia.org/wiki/Eri:AboutTopic/Q25100112"